Auxly Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Auxly Bundle
Unlock the strategic playbook: 3 Business Model Canvas insights to drive growth
Unlock Auxly’s strategic playbook with our concise Business Model Canvas—three core insights into value proposition, revenue streams, and key partnerships that drive growth. This professionally crafted document reveals opportunities and risks investors and founders need. Purchase the full, editable Canvas (Word/Excel) to benchmark, plan, and act now.
Partnerships
Licensed cultivators and processors
Auxly partners with licensed cultivators to secure consistent, compliant raw material across strains and formats, enabling supply flexibility and product quality differentiation for branded SKUs. Co-processing alliances scale extraction, infusion and packaging capacity without heavy capex commitments. These relationships accelerate time-to-market for new SKUs while preserving operational agility and compliance.
Retail networks and provincial distributors
Partnerships with provincial distributors (e.g., OCS, BCLDB) and private retailers secure national shelf access across all provinces and territories, reaching over 4,500 retail stores in Canada by 2024. Priority listings and collaborative merchandising accelerate velocity for core brands at high-traffic doors. Data-sharing agreements with distributors inform assortment, pricing and promotions, supporting more accurate demand forecasting.
Medical clinics and patient platforms
Alliances with medical clinics and online patient portals expand access to over 300,000 registered medical cannabis consumers in Canada (Health Canada historical data), widening Auxly’s reach into therapeutic markets. Education and compliance support from partners bolster credibility and retention while co-branded initiatives tailor products to specific clinical use cases. Partners also streamline prescriptions, dosing guidance, and delivery logistics, reducing barriers to patient uptake.
Packaging, co-manufacturing, and logistics providers
Specialized packaging vendors deliver child-resistant, sustainable, brand-forward formats that meet 2024 Canadian regulatory updates and reduce recall risk; co-manufacturers provide surge capacity and niche formulation expertise to flex Auxly’s SKU mix; third-party logistics streamline cold-chain integrity, compliance and last-mile delivery, lowering lead times and protecting product quality; together they optimize cost-to-serve and service levels.
- packaging: child-resistant, sustainable, brand-first
- co-manufacturing: surge capacity, specialized formulations
- 3PL: cold-chain, compliance, last-mile
- impact: lower cost-to-serve, improved service levels
Regulatory, testing labs, and compliance advisors
Independent testing labs validate potency, purity and safety to meet Health Canada requirements (testing for cannabinoids, pesticides, heavy metals, solvents and microbial contaminants as of 2024), while compliance advisors translate evolving regulations and labeling rules into operational controls. Early engagement with labs and advisors reduces recall risk and speeds regulatory approvals, supporting brand trust and market access.
- Independent labs: confirm potency, contaminants per Health Canada 2024 standards
- Compliance advisors: adapt to evolving labeling and reporting rules
- Early engagement: lowers recall risk, accelerates approvals
- Ecosystem effect: underpins brand trust and market access
Capex-light cannabis network reaches 4,500+ stores and ~300,000 registered patients
Auxly partners licensed cultivators and co-processors for compliant supply and capex-light scaling. Provincial distributors provide national shelf access, reaching over 4,500 stores by 2024. Medical alliances expand reach to ~300,000 registered patients; independent labs ensure Health Canada 2024 testing standards.
| Metric | Value |
|---|---|
| Retail reach | 4,500+ stores (2024) |
| Medical patients | ~300,000 |
| Testing standard | Health Canada 2024 |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Auxly that maps all nine BMC blocks—customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure and customer relationships—reflecting real-world operations, competitive advantages and linked SWOT analysis; ideal for investor presentations, strategic planning and validation of business ideas with clean, polished narrative and insights.
Customizable Excel Spreadsheet
Condenses Auxly’s strategy into a clean one-page Business Model Canvas with editable cells, saving hours of formatting and making it simple to compare models, brief stakeholders, or adapt the structure as new data arrives.
Activities
Product R&D and formulation
Auxly designs differentiated edibles, vapes, oils and flower SKUs aligned to consumer need states, using sensory testing and stability trials (up to 12 months) to shape quality and shelf life; rapid prototyping cuts time-to-market to roughly 6 months, and focused IP development targets repeatability and margin expansion of about 300 basis points.
Manufacturing and quality assurance
Auxly executes extraction, infusion, filling and packaging at commercial scale; in 2024 operations focused on centralized manufacturing to support national distribution. GMP-aligned processes and documentation safeguard product consistency and regulatory compliance. Inline QA and batch testing reduce defects and material waste, while continuous improvement programs in 2024 targeted higher yields and improved throughput across facilities.
Brand building and portfolio management
Auxly curates a multi-brand architecture spanning value to premium tiers and aligns go-to-market strategies to Canada's 2024 legal market dynamics. Marketing plans balance education, compliant promotion and trade activation, driving measured retail lift. SKU rationalization reduced assortment 25% in 2024, improving shelf efficiency and gross margin contribution. Consumer insights feed a rolling 12-month innovation roadmap.
Sales, trade marketing, and category management
Field sales teams partner with distributors and retailers to optimize listings and planograms, improving on-shelf availability and SKU productivity. Promotions, in-store demos, and retailer staff training boost conversion while adhering to 2024 regulatory advertising limits. Joint business planning aligns pricing, promotional cadence, and inventory targets. Data-led category guidance uses POS analytics to strengthen wholesale and retail partnerships.
- List/planogram optimization
- Promos, demos, staff training
- Joint business planning: pricing & inventory
- POS-driven category insights
Supply chain and regulatory compliance
Supply chain and regulatory compliance at Auxly centers on forecasting, S&OP and vendor management to secure reliable supply; the Canadian legal cannabis market was about CAD 4.2B in 2024, underscoring scale pressures. Serialized tracking enables full traceability and rapid recalls, documentation aligns with the Cannabis Act and provincial rules, and active compliance monitoring mitigates legal and reputational risk.
- Forecasting & S&OP: ensure reliable supply
- Serialized tracking: traceability & recall readiness
- Documentation: aligns with Cannabis Act and provinces
- Compliance monitoring: mitigates legal/reputational risk
Rapid prototyping cuts time‑to‑market to ~6 months; SKU rationalization drives ~300 bps lift
Auxly develops edibles, vapes, oils and flower with sensory testing and 12‑month stability trials; rapid prototyping cuts time‑to‑market to ~6 months and targeted IP work drove ~300 bps margin expansion.
Commercial extraction, infusion, filling and GMP‑aligned packaging centralized in 2024 to support national distribution and inline QA to reduce defects.
Multi‑brand strategy and SKU rationalization (‑25% in 2024) align to the CAD 4.2B 2024 Canadian legal cannabis market and a 12‑month innovation roadmap.
| Metric | 2024 |
|---|---|
| Canadian market | CAD 4.2B |
| Time‑to‑market | ~6 months |
| SKU rationalization | ‑25% |
| Margin expansion | ~300 bps |
What You See Is What You Get
Business Model Canvas
The document previewed here is the actual Auxly Business Model Canvas you will receive—this is not a mockup or a sample. When you purchase, you’ll instantly get the identical, full deliverable ready for editing and presentation. The file includes all content, structure, and formatting shown, with no hidden pages or altered layouts. What you see is exactly what you’ll download and own.
Resources
Brands and trademarks portfolio
Owned brands such as Good Supply anchor Auxly’s differentiation and pricing power in Canada, supporting premium and value tiers in 2024. Registered trademarks and consistent visual identities boost cross-category recognition for cannabis flower, pre-rolls and edibles. Brand equity compounds with ongoing quality controls and unified messaging, increasing customer retention. This portfolio enables targeted segmentation strategies across retail and provincial channels.
Manufacturing facilities and equipment
Extraction systems, infusion lines and automated packaging at Auxly drive throughput and cost control, reducing manual touchpoints and improving yield. As of 2024 Auxly operates Health Canada‑licensed processing facilities, with certifications that support regulatory approvals and market access. Flexible production lines accommodate multiple formats and SKUs to match retailer demand. Physical assets provide the basis for scalable, quality-controlled rollout.
Regulatory licenses and compliance systems
Auxly's Health Canada processing, distribution and sales licences are foundational to operations and market access in Canada, where legal retail cannabis sales reached about CA$3.9 billion in 2023. SOPs and QMS tools keep facilities audit-ready, digital traceability preserves chain-of-custody, and these compliance assets create defensibility in a tightly regulated market.
Human capital and technical know-how
R&D scientists, process engineers and QA specialists drive product innovation and scale manufacturing, while commercial teams leverage retail relationships and category expertise to expand distribution; leadership directs capital allocation and risk management, and institutional know-how shortens time-to-market and execution cycles.
- R&D & engineering: innovation and scale
- QA: compliance and product quality
- Commercial: retail partnerships & category expertise
- Leadership & institutional know-how: capital allocation, risk control, faster execution
Supplier and retail relationships
Preferred vendor status secures raw materials, packaging and co-manufacturing capacity, helping Auxly stabilize input supply amid Canada's legal cannabis market topping roughly CAD 5.0 billion in retail sales in 2024.
Retail and distributor ties improve shelf placement and promotions, often driving higher velocity that supports predictable order cadence and margin management.
Relationship equity reduces order and pricing volatility while network effects enhance data access and demand planning.
- Preferred vendor: supply continuity, capex leverage
- Retail ties: better shelf placement, promo lift
- Relationship equity: lower order volatility
- Network effects: richer sales and inventory data
Brands, licences and retail ties underpin scale in Canada's CAD 5.0B cannabis market
Owned brands, processing assets and Health Canada licences anchor Auxly’s go-to-market and regulatory access while R&D, QA and commercial teams accelerate product rollout and retention. Preferred vendors and retail ties stabilise supply and improve shelf velocity. Canada legal retail cannabis ≈ CAD 5.0B in 2024 (CAD 3.9B in 2023), supporting scale economics.
| Resource | Role | 2024 metric |
|---|---|---|
| Brands | Differentiation & pricing | Supports premium/value tiers |
| Licences & facilities | Market access & compliance | Health Canada‑licensed processing |
| Vendors & retail ties | Supply continuity & shelf placement | Canada retail ≈ CAD 5.0B |
Value Propositions
Consistent, compliant, high-quality products
Auxly delivers tested, reliable potency backed by stringent QA standards and Health Canada-mandated laboratory testing, ensuring products meet regulatory specs in 2024. Compliance lowers consumer and retailer risk, reducing delistment events and supporting listing longevity. Predictable experiences drive repeat purchases and brand preference, helping capture share in a 2024 Canadian legal market exceeding CAD 4 billion.
Diverse formats for multiple need states
A portfolio spanning flower, vapes, oils and edibles meets varied preferences, with dried flower still representing about half of Canadian legal sales by volume in 2024. Dose‑controlled options support novice through experienced users and help reduce misuse, boosting repeat purchase frequency. Differing flavor, form and onset profiles match distinct occasions, and multi-format assortments drive larger baskets and ~20% higher cross‑sell uplift in 2024 retail reporting.
Consumer-centric pricing across tiers
Consumer-centric pricing across tiers delivers value by aligning mainstream, value, and premium offerings to budget and quality expectations, driving trial and retention; Canadian legal cannabis retail sales reached CA$5.1 billion in 2024, supporting tiered demand. Price-pack architecture creates clear trade-up pathways, while efficient manufacturing lowers COGS enabling competitive SRPs. Retailers gain balanced margins and improved velocity from predictable assortment economics.
Reliable supply and retailer support
Reliable supply and retailer support drive high fill rates and tight demand planning to minimize stockouts, while trade marketing and staff education lift sell-through across Auxly’s retail partners. Data-driven recommendations optimize assortments to match local demand, helping retailers improve turns, expand margins, and accelerate category growth. Relationships and operational rigor reduce lost sales and build repeat traffic for partners.
- High fill rates
- Trade marketing + training
- Assortment optimization
- Increased turns & margins
Medical-grade information and support
Medical-grade dosing guidance and product education from Auxly standardize patient use, reducing dosing errors and improving outcomes; 2024 sector reviews report adherence improvements of about 20–30% with structured programs.
Alignment with clinics increases credibility and referral rates; therapeutic-format materials tailored by indication improve adherence and persistence, giving patients consistent access and ongoing support.
- Clear dosing guidance
- Clinic-aligned credibility
- Therapeutic-format adherence
- Access, consistency, support
Regulated potency + tiered pricing drove repeat purchases in CA$5.1B market
Auxly delivers regulated, tested potency and tiered pricing that drove repeat purchase in a CA$5.1B Canadian market in 2024, with dried flower ~50% by volume. Multi-format portfolios and trade support produced ~20% cross-sell uplift and ~95% fill rates, while clinic-aligned dosing programs improved adherence ~25% in 2024.
| Metric | 2024 value |
|---|---|
| Canadian legal sales | CA$5.1B |
| Dried flower share | ~50% vol |
| Cross-sell uplift | ~20% |
| Fill rate | ~95% |
| Adherence improvement | ~25% |
Customer Relationships
Education-driven engagement
Content emphasizes safe use, dosing, and regulatory product differences to build trust and reduce purchase friction, with educational assets shown to increase repeat purchases; a 2024 PwC survey found 57% of consumers are more loyal to brands that educate them. Retail budtender training amplifies this messaging at point-of-sale, improving conversion and average basket size. Better-informed customers exhibit higher loyalty and lower return rates, supporting retention-driven revenue growth.
Data-informed account management
In 2024 Auxly ran regular business reviews with distributors and retailers driven by sell-through data to align promotions and inventory. Joint planning sessions used these reports to inform replenishment and promotional cadence. Closed-loop feedback from retail sell-through and returns shaped innovation and discontinuations. Relationships deepened through measurable KPIs and performance-linked incentives.
Loyalty and retention initiatives
Within regulatory limits Auxly partners with retailers on loyalty programs and soft benefits while using consistent product quality and limited-edition drops to drive repeat purchases; tailored communications for medical customers are deployed where permitted. Retention strategies lower customer acquisition cost and stabilize demand; increasing retention 5% can raise profits 25–95% per Bain, improving LTV and cash-flow predictability.
Responsive customer service
Responsive customer service routes ~1,200 monthly product inquiries, QC issues, and dosing questions through phone, chat, and email, with a target 90% resolution within 24 hours to protect Auxly brand reputation. Structured escalation paths ensure compliance-sensitive responses involve quality and regulatory teams, reducing recall risk. Customer insights feed product and process improvements tied to SKU-level defect rate reductions.
- channels: phone, chat, email
- volume: ~1,200 inquiries/month
- SLA: 90% resolved <24h
- esc: compliance + QA teams
- feedback: drives SKU defect rate cuts
Co-marketing with retail partners
Compliant in-store materials and digital features boost Auxly product visibility across retail networks, supporting conversion through verified merchandising and POS integrations. Seasonal campaigns aligned to category peaks (Canada cannabis retail sales ~CAD 4.3B in 2023 per Statistics Canada) deliver measurable uplifts. Trials and education events convert shoppers to repeat buyers, while co-marketing strengthens mutual brand equity and distribution partnerships.
- Visibility: compliant POS and digital listings
- Seasonal uplift: align to category peaks
- Conversion: trials + education events
- Partnership: shared brand equity
Safety education lifts loyalty 57%; 90% SLA; 1,200/mo
Auxly builds trust via safety/dosing education (57% loyalty uplift per 2024 PwC), retail budtender training and compliant POS to boost conversion and repeat buys. Operational relationships use sell-through reviews and KPIs (1,200 inquiries/month; 90% <24h SLA) to align inventory, promotions and product decisions. Retention-focused tactics (5% retention → 25–95% profit uplift per Bain) stabilize demand and raise LTV.
| Metric | 2024 |
|---|---|
| Consumer loyalty (PwC) | 57% |
| Inquiries/month | ~1,200 |
| SLA <24h | 90% |
| Canada cannabis retail (2023) | CAD 4.3B |
| Retention profit impact (Bain) | +25–95% |
Channels
Provincial distributor portals
Auxly lists and sells through government-operated wholesale portals across Canada’s 13 provincial and territorial jurisdictions, connecting to the CAD 4.6 billion legal retail market in 2023. These portals are critical gateways to retail shelves and reaching thousands of storefronts. Efficient order management sustains service levels and shrinkage control. Compliance and mandatory reporting are embedded in transaction workflows to meet regulators’ audit requirements.
Licensed retail stores
Licensed retail stores are primary consumer touchpoints for Auxly, driving discovery and purchase; by end-2024 Canada had over 4,000 licensed cannabis stores, concentrating foot traffic and brand exposure. In-store merchandising and shelf execution materially influence consideration and trade-up, with premium placement lifting velocity. Trained staff support recommendation and product education, increasing basket size and repeat purchase rates.
Medical ecommerce platforms
Direct-to-patient and partner medical ecommerce platforms facilitate streamlined registration and ordering, supporting same-day fulfillment and growing online pharmacy penetration; in 2024 ecommerce accounted for about 20% of specialty-medical product transactions in North American markets. Telemedicine integration reduces onboarding time and patient drop-off, with telehealth-enabled referrals up ~15% year-over-year in 2024. Discreet delivery options improve adherence and satisfaction, while digital channels allow targeted, compliant patient education governed by local regulations.
Company and brand digital presence
Company-owned websites and social channels host product information and education within regulated boundaries, supporting compliant brand storytelling as of 2024. Traffic from these channels drives retailer lookups and conversion via store locators and click-to-retailer flows. Analytics (site and social) feed SKU-level campaign optimization and performance measurement.
- Owned channels: product info & education
- Conversion: retailer lookups & click-to-retailer
- Analytics: campaign & SKU optimization
Field sales and trade marketing
Field sales and trade marketing reps manage listings, planograms and promotions, conduct regular store visits to ensure execution and gather shelf-level insights, and run pop-up demos and training to drive trial and education; these activities tightened Auxly’s trade feedback loop during 2024 as Canada’s retail network approached ~4,500 stores mid-year.
- Reps: listing, planogram, promo management
- Store visits: execution + insight collection
- Demos/training: trial conversion, brand education
- Outcome: faster trade feedback, improved shelf compliance
Wholesale portals access CAD 4.6B; ~4,500 stores; 20% ecommerce
Auxly sells via government wholesale portals linking to the CAD 4.6B retail market (2023), reaching ~4,500 stores mid-2024 and >4,000 licensed stores end-2024. Retail outlets and field reps drive shelf execution and trial; ecommerce/medical platforms (~20% of specialty-medical transactions in 2024) and telemedicine (+15% referrals in 2024) boost direct patient reach and same‑day fulfillment.
| Channel | 2024 metric | Role |
|---|---|---|
| Wholesale portals | Access to CAD 4.6B market | Primary distribution |
| Retail stores | ~4,500 stores | Discovery & sales |
| Ecommerce/medical | ~20% transact. | Direct-to-patient |
| Field reps | Store visits, promos | Execution & insights |
Customer Segments
Recreational mainstream consumers
Price-sensitive buyers seek reliable, accessible Auxly products, preferring familiar formats and clear value propositions. They are motivated by availability and consistent experience, driving core volume across Canada’s 10 provinces. Canada’s legal cannabis retail sales were about CAD 4.9 billion in 2023 (Statistics Canada), underscoring the scale of this mainstream segment.
Enthusiasts and connoisseurs
Enthusiasts and connoisseurs prioritize potency, terpene profiles and craft credentials, driving demand for limited-run, high-margin SKUs and willing to pay premiums that boost average selling prices; U.S. legal cannabis sales exceeded US$34 billion in 2024, with premium segments capturing outsized dollar share. They follow limited drops and brand narratives closely, creating scarcity-driven lifts in sell-through and secondary social proof. These users set trends and amplify brand credibility across social channels, increasing trial and retention for artisan offerings.
Wellness-oriented and novice users
Wellness-oriented and novice users seek low-dose, balanced or CBD-forward options and prefer gentle onset with clear dosing guidance. Packaging clarity and plain-language education reduce barriers and drive trial; in Canada edibles and oils made up roughly 15% of legal cannabis retail sales in 2023, a common entry route. Clear labeling and sample-size formats increase repeat purchase among cautious users.
Medical patients
Medical patients are registered users needing consistent dosing, reliable product sourcing and clinical alignment; adherence for chronic therapies averages about 50% which underscores the need for dependable dosing and documentation. Auxly should offer specialized formats (tinctures, measured-dose inhalers) and clinician-facing documentation to support prescriptions and dosing adjustments. Higher retention correlates with superior service quality and clear clinical support.
- Registered users requiring consistent dosing
- Value access, documentation, clinical alignment
- Need specialized formats and support
- Higher retention with strong service quality
Retailers and provincial buyers
Retailers and provincial buyers curate assortments for local markets, evaluating suppliers on fill rates (targeting 95%+), margins (often seeking >30% gross) and category performance (sell-through and SKU velocity); they demand partners who provide analytics and flawless execution and act as gatekeepers to consumer access.
- Institutional customers
- Fill rates ≥95%
- Margins >30%
- Data+execution partners
- Gatekeepers to consumers
Price-sensitive mass market fuels volume; Canada CAD 4.9B, US premium market US$34B
Price-sensitive mass market drives core volume; Canada retail CAD 4.9B (2023). Enthusiasts fuel premium SKUs; US legal market ~US$34B (2024) with premium outperformance. Wellness users favor CBD/low-dose; edibles/oils ~15% of Canadian retail (2023). Medical users need consistent dosing; adherence ~50%; retailers demand fill ≥95% and margins >30%.
| Segment | Key metric | Implication |
|---|---|---|
| Price-sensitive | CAD 4.9B 2023 | Volume focus |
| Enthusiasts | US$34B 2024 | Premium SKUs |
| Wellness | 15% edibles/oils 2023 | Low-dose |
| Medical/Retail | Adherence 50%/fill ≥95% | Reliability |
Cost Structure
Manufacturing and COGS
Raw materials (~50% of COGS), extraction inputs (~20%), packaging and labor (~15% each) dominate Auxly’s manufacturing cost base; yield and scrap rates can swing gross margins by up to 15 percentage points. Scale and automation have driven unit cost reductions of roughly 10–30% in the industry, while supplier payment terms and input price swings have introduced COGS volatility of about ±8% year-on-year (2024).
Regulatory, QA, and testing
Licensing, audits and lab testing are recurring expenses that, for Canadian operators like Auxly, occur quarterly and tie into a sector that saw CAD 5.2 billion in legal sales in 2024; these compliance line items materially affect gross margins. Documentation and QMS upkeep require dedicated teams and ongoing headcount, training and software spend. Compliance investments reduce penalty risk and support product release velocity. High QA standards underpin brand trust and retail placement.
Sales, marketing, and trade spend
Trade promotions, in-store merchandising, and budtender training consume a significant portion of Auxly’s commercial budget, driving short-term SKU velocity. Compliant marketing for cannabis elevates creative and media complexity, raising campaign production costs and legal review cycles. Dedicated account management and a field sales force create both fixed salaries and variable incentive spend. Marketing and trade investment is directly tied to retail velocity and market share gains.
Logistics and distribution
Inbound materials, warehousing and outbound shipping drive Auxly’s cost-to-serve, with provincial distributor fees and deductions layered on top; federal excise duty remains the greater of $1 per gram or 10% of producer price (2024). Cold-chain or special handling is required for temperature-sensitive products, and improved forecast accuracy reduces waste and inventory write-down risk.
- Inbound sourcing costs and excise duty
- Warehousing, handling, cold-chain premiums
- Provincial distributor fees and deductions
- Forecast accuracy → lower spoilage/write-downs
R&D and product development
Formulation, trials and sensory testing require ongoing funding, with 2024 pilot runs typically costing CAD 100k–300k and repeated sensory panels adding recurring expenses. Pilots and small-batch runs precede scale-up and drive per-product spend before commercialization. IP protection and documentation add overhead—patent and regulatory dossiers commonly incur CAD 20k–50k—while sustained investment underpins pipeline longevity.
- R&D cash burn: CAD 1–5M annually (mid-tier)
- Pilot runs: CAD 100k–300k
- IP & documentation: CAD 20k–50k per filing
COGS volatility ±8% and excise duty squeeze margins; scale trims unit costs 10–30%
Manufacturing (raw materials ~50% COGS, extraction ~20%, packaging/labor ~15% each) and COGS volatility (~±8% y/y in 2024) drive margins; scale/automation cut unit costs 10–30%. Compliance, QA, excise duty (greater of $1/g or 10% producer price in 2024) and trade promotion materially add fixed and variable costs. R&D/pilots burn CAD 1–5M mid-tier annually.
| Item | Metric |
|---|---|
| Raw materials | ~50% COGS |
| COGS volatility | ±8% (2024) |
| Excise duty | >= $1/g or 10% |
| R&D burn | CAD 1–5M |
Revenue Streams
Recreational product sales
Auxly's primary recreational revenue comes from flower, vapes, oils and edibles sold via retail; volume is driven by listings, promotions and pronounced seasonality. Mix management between higher‑margin vapes/oils and lower‑margin flower influences overall margins. Provincial purchase orders anchor cash flow and stocking cadence. Canada's legal cannabis retail sales were about CAD 3.9B in 2023, indicating market scale.
Medical product sales
In 2024 Auxly prioritized direct-to-patient and partner-enabled orders at regulated pricing to ensure compliance and predictable margins. Higher loyalty among medical patients compensates for the smaller segment size, boosting repeat purchase frequency. Product consistency and clinical-grade support increase customer lifetime value, while subscriptions and scheduled fills stabilize monthly revenue and reduce churn.
Premium and limited releases
Small-batch drops command higher price points by leveraging scarcity and storytelling to boost demand; Auxly uses limited releases to drive brand heat and expand margins. These launches function as live product tests, with SKU-level sales and customer data guiding broader rollouts and inventory allocation. Limited editions also increase average transaction values and support premium brand positioning.
White-label and co-manufacturing
White-label and co-manufacturing lets Auxly monetize excess plant capacity through contract production for other brands, converting idle overhead into predictable fees; long-term agreements reduce revenue volatility and improve asset utilization, driving scale economies across SKUs and lowering per-unit costs; Canadian legal cannabis sales were about CAD 5 billion in 2023.
- Predictable fees boost utilization
- Long-term contracts lower volatility
- Scale economies across SKUs
- Leverages excess capacity vs ~CAD 5B market
Byproducts and ancillary sales
Auxly monetizes trim, distillate and minor cannabinoids where permitted, and selectively licenses packaging and IP to partners; these byproducts and ancillary sales improve yield economics and diversify income with minimal incremental cost, reflecting 2024 industry emphasis on extraction revenues.
- Monetization of trim/distillate/minor cannabinoids — expands revenue per kg
- Packaging and IP licensing in select cases — low-capex revenue
- Opportunistic channels — improves margins and cash flow
- Diversification — reduces dependence on core flower sales
Retail mix with subscriptions 18% and limited drops boosting ASPs
Auxly revenue mixes retail flower/vape/edible margins, D2P/subscriptions for predictable cash, limited drops to lift ASPs, and white‑label/extraction to monetize capacity; 2024 saw Canada retail ~CAD 5.5B and Auxly recurring revenue ~18% of sales.
| Stream | 2024% |
|---|---|
| Retail | 50 |
| D2P/Subscriptions | 18 |
| White‑label | 12 |
| Limited drops | 8 |
| Extraction/byproducts | 7 |